http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오인재,최유덕,최송,김순진,김규식,송상윤 대한흉부외과학회 2010 Journal of Chest Surgery (J Chest Surg) Vol.43 No.6
Tracheobronchopathia osteochondroplastica (TO) is an uncommon benign disease of an unknown etiology and it affects the cartilaginous walls of large airways. Most cases of TO have been reported to involve the lower two-thirds of the trachea and the proximal bronchi. Unlike the usual cases of TO, exclusive bronchial involvement and the formation of a solitary mass are very rare. We experienced an unusual case that had exclusive bronchial involvement and the formation of a solitary mass and this all mimicked lung malignancy. After surgical resection, we were finally able to diagnose the mass as bronchopathia osteochondroplastica. 기관골연골증이나 기관지골연골증은 큰 기도의 연골에 생기는 잘 알려지지 않는 병리를 가진 매우드문 양성질환으로 보고되고 있다. 대부분 하부기관이나 근위부 기관지에서 발생하는 것으로 보고되고 있다. 대부분의 기관골연골증과는 달리, 기관지를 벗어나서 종괴를 형성하는 기관골연골증은 매우드물다. 그러나 저자들은 기존의 보고와는 다르게 엽기관지에 종괴를 형성하여 육안적으로 폐암과유사한 형태를 지닌 기관골연골증을 치험하였으며, 수술적 절제 후 기관지골연골증임을 진단할 수있었다.
오인재,최유덕,윤성훈,유진영,이보람,반희정,권용수,김규식,김유일,임성철,김영철 대한결핵 및 호흡기학회 2013 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.116 No.-
Background: The c-MET is associated with tumor progression and acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study was to evaluate the prevalence and predictive role of c-MET and EGFR mutation in non-small cell lung cancer (NSCLC). Methods: This is a multicenter prospective observational study for patients with stage IV or recurrent NSCLC who have progressive disease after 1st line chemotherapy. The primary outcome is to measure the rates of c-MET expression/amplification and EGFR mutation in tumor tissue. MET expression was evaluated by immunohistochemistry (IHC) and gene copy number was assessed by silver in situ hybridization (SISH). EGFR mutations were analyzed by CobasTM method. Results: A total of 112 patients were enrolled and major histologic types were adenocarcinoma (65%). MET was overexpressed (MET IHC-positive) in 57.1% of the patients and the median progression-free survival (PFS) was shorter (51 vs 56 days, p=0.034). MET amplification and high polysomy (MET SISH-positive) were observed in 2.7% and 10.7%, but there was no correlation with response and PFS. The detection rate of EGFR mutation was 13.5% (19 deletion: 5, L858R: 5, exon 20 insertion: 2 cases). The response rate of erlotinib was significantly higher in EGFR sensitive mutant (60.0% vs. 1.6%, p<0.001) and the median PFS showed longer tendency (52 vs 116 days, p=0.093). Conclusion: In this interim analysis, we confirmed EGFR mutation is strong predictive marker and c-MET overexpression may negatively affect PFS in 2nd line erlotinib treatment.Background: The c-MET is associated with tumor progression and acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study was to evaluate the prevalence and predictive role of c-MET and EGFR mutation in non-small cell lung cancer (NSCLC). Methods: This is a multicenter prospective observational study for patients with stage IV or recurrent NSCLC who have progressive disease after 1st line chemotherapy. The primary outcome is to measure the rates of c-MET expression/amplification and EGFR mutation in tumor tissue. MET expression was evaluated by immunohistochemistry (IHC) and gene copy number was assessed by silver in situ hybridization (SISH). EGFR mutations were analyzed by CobasTM method. Results: A total of 112 patients were enrolled and major histologic types were adenocarcinoma (65%). MET was overexpressed (MET IHC-positive) in 57.1% of the patients and the median progression-free survival (PFS) was shorter (51 vs 56 days, p=0.034). MET amplification and high polysomy (MET SISH-positive) were observed in 2.7% and 10.7%, but there was no correlation with response and PFS. The detection rate of EGFR mutation was 13.5% (19 deletion: 5, L858R: 5, exon 20 insertion: 2 cases). The response rate of erlotinib was significantly higher in EGFR sensitive mutant (60.0% vs. 1.6%, p<0.001) and the median PFS showed longer tendency (52 vs 116 days, p=0.093). Conclusion: In this interim analysis, we confirmed EGFR mutation is strong predictive marker and c-MET overexpression may negatively affect PFS in 2nd line erlotinib treatment.